Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase: Enrolling; Phase 2

Conditions: Cutaneous T-cell Lymphoma

Treatments: Drug: Chidamide; Drug: Sintilimab

Study type: Interventional

Funder types: Other

Identifiers

NCT04296786

PUMCH-NHL-006

Details and patient eligibility

About

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of Sintilimab combined with Chidamide in the treatment of relapsed/refractory cutaneous T-cell lymphoma.

Full description

This is a single-arm phase 2 study with fixed does of combined Sintilimab and Chidamide regimen. This regimen is repeated every 21 days. Sintilimab (200mg) is administered intravenously on day 1 of every cycle. Chidamide is used 20mg twice per week continuously. From the beginning of the trial, sindilimab will be used for 96 weeks, until disease progress, intolerable toxicity or patient/investigator discretion. Patients will continue to receive Chidamide treatment until disease progression, unacceptable toxicity, or patient/investigator discretion.

The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment. The patients who achieve complete remission (CR), partial remission (PR), and stable disease (SD) will receive further treatment. The patients with progressed disease (PD) will be continue on the treatment and reassess after 4-8 weeks to rule out false progression. On confirmation of PD , patients will be withdrawn from the trial and receive salvage regimens.

Enrollment: 52 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed cutaneous T-cell lymphoma according World Health Organization (WHO) classification.
• ECOG≤2
• Patients with measurable lesions, with or without extra-dermal lesions, clinical stage of IIB-IVB.
• Patients received at least one systemic treatment previously and achieved no remission or relapsed after first-line treatment.
• Absolute neutrophil count (ANC）≥0.75×109/L，platelet (PLT) ≥ 50×109/L，hemoglobin (HGB）≥ 80 g/L
• Thyroid stimulating hormone (TSH) within normal range

Exclusion criteria

• Pre-existing uncontrolled active infection
• Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN), total bilirubin (TBIL) >1.5 times ULN, serum creatinine >1.5 times ULN
• Patients with clinically significant QT interval prolongation (male > 450ms, female > 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), acute coronary syndrome (ACS) within 1 year, congestive heart failure (CHF), and symptomatic coronary heart disease.
• Patients who have received organ transplantation or hematopoietic stem cell transplantation.
• Active bleeding or recent thrombotic disease
• Patients with known interstitial lung disease
• Patients with active autoimmune disease or history of autoimmune disease in the past 2 years
• Patients with CNS involvement
• Pregnant or lactating women
• History of mental illness

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

52 participants in 1 patient group

Chidamide plus Sintilimab

Experimental group

Description:

Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.

Treatment:

Drug: Chidamide

Drug: Sintilimab